DJIA 16,461.32 -153.49 -0.92%
NASDAQ 4,382.85 -36.63 -0.83%
S&P 500 1,927.11 -14.17 -0.73%
market minute promo

VIVUS, Inc. (NASDAQ: VVUS)



company name or ticker

Assessing Arena Pharmaceutical Belviq Sales And The Impact Of TV Ads

Could Arena Pharmaceuticals Inc. Be Running Out of Money?

Biotech stocks running out of money is a common concern for investors of clinical-stage and early commercial stage stocks. Let's take a closer look at Arena Pharmaceuticals' current cash situation and determine whether or not current investors should be worried.

Orexigen Launches Contrave - Watch For Traction

What To Watch For As Orexigen's Launch Approaches

Emergent BioSolutions Revamps Business to Drive Earnings - Analyst Blog

3 Biotech Stocks Near 52-Week Lows Worth Buying

These may be cheap biotech stocks, but they may not be cheap for long according to the three analysts we asked.

Halozyme's PEGPH20 Receives FDA Orphan Drug Designation - Analyst Blog

Halozyme's PEGPH20 Receives FDA Orphan Drug Designation - Analyst Blog

Regeneron's Eye Drug Eylea Wins Another FDA Approval - Analyst Blog

Orexigen On A Tear - In The Wrong Direction

Is VIVUS Inc. a Short Sell?

Shares of VIVUS Inc. have crashed by over 60% in the past year. Is the stock still a good short sell?
See More Articles...